All posts

WELL Health could unlock value with U.S. divestiture, Stifel says

Stifel analyst Justin Keywood says WELL Health Technologies (WELL Health Technologies Stock Quote, Chart, News, Analysts, Financials TSX:WELL) could unlock big value with the divestiture of some U.S. assets.

On June 18 in Toronto, WELL Health hosted its annual investor day, summarizing the progress that has brought it to nearly a billion dollars in revenue and highlighting the opportunities it sees going forward.

Keywood says WELL is trading at a discount and with a myriad of opportunities in the Canadian market and could free up a lot of cash to act on them.

“WELL has executed on 80 transactions, where the sum-of-parts could be worth more than the whole,” he wrote. “WELL detailed potential divestitures of U.S. assets, WISP and Circle Medical, not nearly reflected in current valuation, we believe. Circle Medical has grown from US$5m sales since its 2020 acquisition to a ~US$95mm run-rate. WISP has similarly seen rapid growth and focused in women’s health, with comp (HIMS) trading at favorable valuation.

In a research update to clients Keywood maintained his “Buy” rating and $10.00 price target on WELL.”

Keywood says the M&A pipeline remains robust for WELL.

“WELL still has a wide pipeline for M&A, particularly in healthcare services assets in Canada,” he wrote. “WELL highlighted an average of 300bps in EBITDA margin expansion achieved on M&A, including heavy technology implementation. WELL’s 24-asset pipeline currently, includes about half, related to absorption prospects, with only a nominal fee paid and as low as 0.02x sales. The other half are better margin-generating assets and could be acquired for 4x-8x EBITDA, by our math. WELL’s current leverage is ~2.7x or 3.5x with the convertible debenture but $55mm in FCF expected to be generated in 2024 could be used for M&A. Further, +$250mm of contributions from WISP/Circle Medical may finance future M&A.”

Disclosure: WELL Health is an annual sponsor of Cantech Letter and Nick Waddell is a shareholder of the company.

Tagged with: well
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Haywood says this pot stock is a winner

In a Nov. 5 report, Haywood Capital Markets analyst Neal Gilmer maintained his “Buy” rating and C$15.00 target price on… [Read More]

10 hours ago

MustGrow Biologics CEO Corey Giasson talks to Cantech Letter

Saskatoon-based MustGrow Biologics (MustGrow Biologics Stock Quote, Chart, News, Analysts, Financials TSXV:MGRO) is bringing biotechnology and regenerative agriculture together to… [Read More]

14 hours ago

DATA Communications Management CFO James Lorimer talks to Cantech Letter

After nearly doubling in size through a major acquisition, DATA Communications Management (DATA Communications Management Stock Quote, Chart, News, Analysts,… [Read More]

15 hours ago

Should you sell your Lightspeed stock?

In a Nov. 6 report, ATB Capital Markets analyst Martin Toner raised his target price on Lightspeed Commerce (Lightspeed Commerce… [Read More]

17 hours ago

Cresco Labs is a buy, this analyst says

On Nov. 5, Haywood Capital Markets analyst Neal Gilmer maintained his “Buy” rating and US $2.00 target price on Cresco… [Read More]

17 hours ago

Trulieve Cannabis just got a massive price target raise from this analyst

In a Nov. 6 report, Beacon Securities analyst Russell Stanley raised his target price on Trulieve Cannabis (Trulieve Cannabis Stock… [Read More]

2 days ago